RCKT

Rocket Pharmaceuticals Inc

NASDAQ: RCKT · HEALTHCARE · BIOTECHNOLOGY

$3.64

-5.82% today

Updated 2026-06-05

Market cap

$315.57M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.87

Dividend yield

—

52W range

$2 – $5

Volume

3.1M

Market cap

$315.57M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.87

Dividend yield

—

52W range

$2 – $5

Volume

3.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-4.6

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$9.30

+155.49%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy6 Buy6 Hold1 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.10x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -4.60 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-45.49M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-221.86M	$-245.59M	$-258.75M	$-223.12M	$-47.59M
EPS	—	—	—	—	$-1.87
Free cash flow	$-186.76M	$-211.39M	$-215.59M	$-190.45M	$-45.49M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-05-13	WILSON, MARTIN	Sale	3,361	$3.61
2026-05-13	SHAH, GAURAV	Sale	2,728	$3.61
2026-05-13	MILITELLO, JOHN	Sale	855	$3.61

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
RCKT	$315.57M	31	4.3	3.0	5.0	6.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Rocket Pharmaceuticals Inc trades at $3.64. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -4.60, it sits in the distress.

Frequently asked questions

What is Rocket Pharmaceuticals Inc's stock price?

Rocket Pharmaceuticals Inc (RCKT) trades at $3.64.

Is Rocket Pharmaceuticals Inc overvalued?

Rocket Pharmaceuticals Inc carries a Smart Value Score of 31/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Rocket Pharmaceuticals Inc (RCKT)?

The 12-month analyst consensus target is $9.30, about 155.5% above the current $3.64. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Rocket Pharmaceuticals Inc's Altman Z-Score is -4.60, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.rocketpharma.com

Quick metrics

P/S ratio—

ROE-87.96%

Beta0.52

50D MA$3.57

200D MA$3.57

Shares out0.11B

Float0.09B

Short ratio—

Avg volume3.1M

Performance

1 week-9.97%

1 month-6.63%

3 months-5.38%

YTD+0.28%

1 year—

3 years—

5 years—

Compare

RCKT vs LLY →RCKT vs JNJ →RCKT vs ABBV →Stock screener →